AbbVie's Venclexta Combo Fails In Late-Stage Leukemia Study
Zacks Investment Research | Mar 02, 2020 07:57AM ET
AbbVie (NYSE:ABBV) announced that a phase III study — VIALE-C — evaluating a combination regimen of its blood cancer drug, Venclexta (venetoclax), failed to meet primary endpoint. The study evaluated Venclexta in combination with low-dose cytarabine (“LDAC”) for improvement in overall survival (“OS”) in previously untreated patients with acute myeloid leukemia (“AML”) who are ineligible for intensive chemotherapy.
Data from the study showed that Venclexta plus LDAC failed to show statistically significant improvement in OS compared to LDAC plus placebo in AML patients.
The Venclexta combination regimen reduced risk of death by 25% versus LDAC with placebo. At the time of the primary analysis, median OS for Venclexta combo arm was 7.2 months versus 4.1 months for the comparator arm. An additional six months of follow up showed that treatment with Venclexta plus LDAC led to increase in median OS of 8.4 months and 4.1 months for LDAC plus placebo. Moreover, Venclexta combo also achieved complete remission in 27.3% patients compared to 7.4% for the LDAC plus placebo regimen.
Although Venclexta-LDAC combination regimen failed to show statistically significant improvement of OS, data indicated clinical activity in patients. The company has provided the study results to the FDA and other global health authorities.
AbbVie’s shares have increased 7.9% in the past year against the industry ’s decrease of 2.2%.
Venclexta is approved in combination with chemotherapy — azacitidine, decitabine or LDAC — is approved under accelerated pathway for the treatment of newly-diagnosed AML. The drug is also approved as monotherapy and in combination with Roche’s Gazyva or Roche/Biogen’s (NASDAQ:BIIB) Rituxan for treating chronic lymphocytic leukemia or small lymphocytic lymphoma. AbbVie co-develops and co-commercializes Venclexta with Roche (OTC:RHHBY) .
The VIALE-C study failure does not change the drug’s approved indications for now. AbbVie is evaluating Venxclexta in combination with azacitidine in another phase III study, VIALE-A, in patient population similar to VIALE-C study.
AbbVie has a strong AML research program with several clinical studies evaluating Venclexta and other pipeline candidates. The company is also strengthening its oncology portfolio through label expansions of marketed drugs as well as new drug development. It believes that oncology will be its major growth driver over the next 10 years. Venclexta along with another key cancer drug, Imbruvica, generated combined revenues of nearly $5.5 billion in 2019 and double-digit growth is expected in 2020. Please note that AbbVie co-develops and co-commercializes Imbruvica with J&J (NYSE:JNJ) .
Get The News You Want
AbbVie Inc. Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.